Biogen Idec Looks To Develop PML Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Alnylam’s RNAi technology will be directed at progressive multifocal leukoencephalopathy, the brain disease associated with Biogen’s MS therapy Tysabri.
You may also be interested in...
Biogen Idec CEO James Mullen: An Interview With “The Pink Sheet” DAILY
Company is “open for business” on deals, Mullen says during break at Massachusetts Biotechnology Council investor conference.
Biogen Idec CEO James Mullen: An Interview With “The Pink Sheet” DAILY
Company is “open for business” on deals, Mullen says during break at Massachusetts Biotechnology Council investor conference.
Alnylam Seeks Deals As RNAi Interest Heats Up
Company looking to build on current deals with Merck and Novartis, COO says in interview with "The Pink Sheet" DAILY.